AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients

Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1. Aryl hydrocarbon receptor interacting protein (AIP) mutations are associated with an aggressive, inheritable form of acromegaly that responds poorly to SST2-specific somatostatin analogs (SSA). The role of pasireotide,...

Full description

Bibliographic Details
Main Authors: Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, Albert Beckers
Format: Article
Language:English
Published: Bioscientifica 2019-04-01
Series:Endocrine Connections
Subjects:
acromegaly
AIP
somatostatin analog
FIPA
resistant
pituitary adenoma
pasireotide
octreotide
lanreotide
thyroid cancer
Online Access:https://ec.bioscientifica.com/view/journals/ec/8/4/EC-19-0004.xml

Internet

https://ec.bioscientifica.com/view/journals/ec/8/4/EC-19-0004.xml

Similar Items